Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Onkologie|June 24, 2009
[Laparoscopic surgery and adjuvant therapy for colon cancer]Stefan Kubicka, Michael Geissler, Hans-Peter Bruch, et al.
Onkologie|December 17, 2008
[Adjuvant therapy of colon carcinoma]Tanja Trarbach, Stefan Kubicka, Ulrich Hacker, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 18, 2010
Safety distance in the resection of colorectal lung metastases: a prospective evaluation of satellite tumor cells with immunohistochemistryStefan Welter, Dirk Theegarten, Tanja Trarbach, et al.
Investigational New Drugs|July 6, 2012
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomasTanja Trarbach, Marta Przyborek, Norbert Schleucher, et al.
Apoptosis : an International Journal on Programmed Cell Death|May 24, 2007
Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platformsClaudia Alexandra Dumitru, Alexander Carpinteiro, Tanja Trarbach, et al.
BMC Cancer|July 21, 2014
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancerGunnar Folprecht, Susanne Hamann, Katharina Schütte, et al.
Journal of Occupational Rehabilitation|November 8, 2025
Evaluation of the Socio-Medical Assessment of Work Capacity in Patients with Colorectal Cancer in German Rehabilitation Clinics: Its Diagnostic Accuracy for Actual Return to Work and the Physicians' Views on Potential Changes in Current PracticeTomislav Vlaski, Reiner Caspari, Harald Fischer, et al.
Antioxidants & Redox Signaling|June 20, 2007
Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapyGeorgios Grammatikos, Volker Teichgräber, Alexander Carpinteiro, et al.
Onkologie|December 17, 2008
[Treatment of gastric cancer]Florian Lordick, Karsten Ridwelski, Salah-Eddin Al-Batran, et al.
BMC Cancer|July 27, 2017
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)Thomas Decker, Friedrich Overkamp, Siegfried Rösel, et al.
Pageof 5